The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study, which is being conducted at 100 centers throughout the United
States, is to determine whether Lantus, a long-acting insulin injection, either alone or in
combination with metformin, is effective in reducing C-reactive protein (CRP) in adults with
type 2 diabetes. CRP is a marker of chronic low-level inflammation, a new risk factor for
diabetes, heart attack, stroke, and other cardiovascular events.